Ticagrelor

PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

Retrieved on: 
Thursday, April 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, LinkedIn, Degenerative disease, Ticagrelor, Pharmacokinetics, PHAS, Interest, Conference, Hypertension, Twitter, CA, Partnership, Pharmaceutical industry

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference taking place virtually on Thursday, April 14, 2022 from 1:30 2:10 pm ET.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference taking place virtually on Thursday, April 14, 2022 from 1:30 2:10 pm ET.
  • The webcast replay will be available for 90 days after the conclusion of the live presentation.
  • PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases.
  • For more information, please visit www.phasebio.com , and follow us on Twitter @PhaseBio and LinkedIn .

PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bleeding, Degenerative disease, Ticagrelor, PHAS, Aspirin, Food, Bentracimab, American College, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Patient, Pharmaceutical industry, Medical imaging, BENTRACIMAB (PB2452), PHASEBIO

The Phase 2b pivotal trial was conducted concurrently with the companys ongoing REVERSE-IT Phase 3 pivotal trial of bentracimab, as agreed upon with the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 meeting in July 2019 .

Key Points: 
  • The Phase 2b pivotal trial was conducted concurrently with the companys ongoing REVERSE-IT Phase 3 pivotal trial of bentracimab, as agreed upon with the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 meeting in July 2019 .
  • In the Phase 2b trial, bentracimab significantly restored platelet function within five minutes of administration (p
  • These complete safety and efficacy data from the Phase 2b trial are consistent with results from PhaseBios previously completed Phase 1 trial, conducted in healthy younger volunteers treated with ticagrelor alone and not aspirin, and its Phase 2a trial, conducted in healthy, older (ages 50-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin and with topline results previously announced for the Phase 2b trial on November 3, 2021.
  • In November 2021, PhaseBio completed a Phase 2b trial in which bentracimab was investigated in older subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin.

PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

Retrieved on: 
Tuesday, March 8, 2022
Research, FDA, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Chemistry, Private Securities Litigation Reform Act, Ticagrelor, Rapids, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Patient, Pharmacokinetics, Bentracimab, New England, Research, Forward-looking statement, Food, PHAS, Biologics license application, SVP, U.S. Securities and Exchange Commission, LinkedIn, Hypertensive emergency, PPQ, FDA, The New England Journal of Medicine, Mark (given name), CMC, Company, CA, NEJM, American Heart Association, Clinical trial, Process performance qualification protocol, Aspirin, Bleeding, VIP, Partnership, Breakthrough therapy, Disclosure, Hypertension, Fine chemical, Pharmaceutical industry, Bentracimab (PB2452), PhaseBio, Bentracimab (PB2452), PhaseBio, BENTRACIMAB (PB2452), PHASEBIO

The PPQ campaign consisted of multiple commercial scale runs required for the validation of the bentracimab manufacturing process and the demonstration of batch-to-batch manufacturing consistency, at commercial scale.

Key Points: 
  • The PPQ campaign consisted of multiple commercial scale runs required for the validation of the bentracimab manufacturing process and the demonstration of batch-to-batch manufacturing consistency, at commercial scale.
  • "We are pleased with the exceptional efforts of our manufacturing partners, BIOVECTRA Inc. (Windsor, Nova Scotia) and Berkshire Sterile Manufacturing (Lee, MA), said Susan Arnold, Ph.D., SVP, Technical Operations at PhaseBio.
  • Establishing a commercial-scale manufacturing process early in the development of bentracimab has been a key strategic imperative for PhaseBio, said Jonathan Mow, Chief Executive Officer at PhaseBio.
  • These forward-looking statements speak only as of the date hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation to update these statements except as may be required by law.

PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Partnership, PHAS, Twitter, Pharmacokinetics, VIP, CA, Interest, LinkedIn, Ticagrelor, Degenerative disease, Hypertension, Conference, Hypertensive emergency, Pharmaceutical industry

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowens 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm 1:50 pm ET.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowens 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm 1:50 pm ET.
  • The webcast replay will be available for 90 days after the conclusion of the live presentation.
  • PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases.
  • For more information, please visit www.phasebio.com , and follow us on Twitter @PhaseBio and LinkedIn .

PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session

Retrieved on: 
Thursday, February 10, 2022
FDA, Health, General Health, Public Relations, Investor Relations, Pharmaceutical, Communications, Other Science, Research, Genetics, Science, Clinical Trials, Hypertension, Cone Health Women's Hospital, Private Securities Litigation Reform Act, Disclosure, Aspirin, NEJM, Hypertensive emergency, Harvard Medical School, Research, Company, U.S. Securities and Exchange Commission, Ticagrelor, Bentracimab, Breakthrough therapy, Clinical trial, American College, The New England Journal of Medicine, FDA, Patient, CA, Safety, American Heart Association, BLA, Pharmacokinetics, Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cardiology, Food, PHAS, LinkedIn, Bleeding, Partnership, MPH, VIP, New England, Forward-looking statement, Pharmaceutical industry, Medicine, Bentracimab (PB2452), PhaseBio, BENTRACIMAB (PB2452), PHASEBIO

In November 2021, PhaseBio presented interim results from the REVERSE-IT trial during a Late-Breaking Science Session at the 2021 American Heart Association Scientific Sessions.

Key Points: 
  • In November 2021, PhaseBio presented interim results from the REVERSE-IT trial during a Late-Breaking Science Session at the 2021 American Heart Association Scientific Sessions.
  • Data from the Phase 1 clinical trial of bentracimab in healthy volunteers was published in the New England Journal of Medicine in March 2019.
  • Additionally, the Phase 2a trial investigated a bentracimab regimen for the reversal of supratherapeutic doses of ticagrelor in healthy younger subjects.
  • In November 2021, PhaseBio completed a Phase 2b trial in which bentracimab was investigated in healthy, older subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin.

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

Retrieved on: 
Tuesday, February 8, 2022
NASDAQ, CE marking, Liver disease, Adsorption, Office of Inspector General, U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute, Private Securities Litigation Reform Act, Cardiopulmonary bypass, Cytokine release syndrome, SOCOM, DOAC, Company, Facebook, Twitter, Myoglobin, Cytokine adsorbing column, Army of the United States, Annual report, Ticagrelor, Union, Risk, Investor relations, NIH, FDA, Patient, U.S. Department of Defense Strategy for Operating in Cyberspace, Air Force Materiel Command, National, Professional corporation, DARPA, Adult, Cytosorbents Corporation, Blood, HHS, SEC, Death, Rivaroxaban, Trauma, Federal, Bilirubin, NHLBI, Safe, United, Lung, United States Special Operations Command, Judgement, Manifest and latent functions and dysfunctions, COVID-19, Pharmaceutical industry

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.

Key Points: 
  • It is recommended that participants dial in approximately 10 minutes prior to the start of the call.
  • An archived recording of the conference call will be available under the Investor Relations portion of the company's website at https://cytosorbents.com/investor-relations/financial-results/ .
  • CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
  • This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995.

CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, February 3, 2022
Bilirubin, Private Securities Litigation Reform Act, CE marking, Professional corporation, Army of the United States, Risk, Union, National Heart, Lung, and Blood Institute, Ticagrelor, Liver disease, Patient, NASDAQ, HHS, SEC, National, Cytokine adsorbing column, Adsorption, Twitter, Cytosorbents Corporation, United States Special Operations Command, Cytokine release syndrome, COVID-19, Death, Trauma, Investor relations, Facebook, Rivaroxaban, Air Force Materiel Command, Adult, DARPA, Federal, Annual report, Company, Blood, United, Manifest and latent functions and dysfunctions, Myoglobin, Cardiopulmonary bypass, Office of Inspector General, U.S. Department of Health and Human Services, DOAC, NIH, NHLBI, Safe, U.S. Department of Defense Strategy for Operating in Cyberspace, FDA, Lung, Event, Conference, SOCOM, Judgement, Pharmaceutical industry

MONMOUTH JUNCTION, N.J., Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.

Key Points: 
  • MONMOUTH JUNCTION, N.J., Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.
  • On Thursday, February 17, 2022, Dr. Phillip Chan, CytoSorbents' Chief Executive Officer, will participate in a virtual fireside chat during the 11th Annual SVB Leerink Global Healthcare Conference at 10:00 a.m. Eastern time.
  • An archived recording of CytoSorbents' presentations at both investor conferences will be available under the Investor Relations portion of the Company's website at Events & Presentations - Cytosorbents , and will be available for 30 days.
  • CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.

New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology

Retrieved on: 
Monday, January 24, 2022
Zero, Patient, Cardiopulmonary bypass, Hemostasis, Professional corporation, Mortality, Disease, NASDAQ, Cytosorbents Corporation, AstraZeneca, DOAC, Risk, Drainage, Hospital, Medicine, Ticagrelor, Rivaroxaban

Dr. Efthymios N. Deliargyris, Chief Medical Officer of CytoSorbents stated, "This new publication extends the evidence for clinical benefit with intraoperative antithrombotic removal using our hemoadsorption technology beyond coronary artery bypass grafting (CABG) and into additional complex cardiac operations, such as acute type A dissection aortic surgery.

Key Points: 
  • Dr. Efthymios N. Deliargyris, Chief Medical Officer of CytoSorbents stated, "This new publication extends the evidence for clinical benefit with intraoperative antithrombotic removal using our hemoadsorption technology beyond coronary artery bypass grafting (CABG) and into additional complex cardiac operations, such as acute type A dissection aortic surgery.
  • Furthermore, it validates our strategy to include patients undergoing urgent aortic surgery in both the STAR-T and STAR-D trials.
  • The U.S. STAR-T and STAR-D trials, evaluating the use of DrugSorbATR for intraoperative removal of antithrombotic drugs during urgent cardiothoracic surgery, are our top priorities.
  • CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.

PhaseBio Provides Pemziviptadil (PB1046) Program Update

Retrieved on: 
Tuesday, December 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, WHO, Cardiomyopathy, Adult, Bentracimab, FDA, Time, ELP, Vasoactive intestinal peptide, Hypertensive emergency, Half-life, Hypertension, LinkedIn, PHAS, Disclosure, Duchenne muscular dystrophy, CA, COVID-19, U.S. Securities and Exchange Commission, Research, VIP, PAH, Partnership, Private Securities Litigation Reform Act, Pharmacokinetics, Forward-looking statement, Program, Pulmonary hypertension, Population, Ticagrelor, Patient, Pharmaceutical industry, Pemziviptadil (PB1046), PhaseBio, PEMZIVIPTADIL (PB1046), PHASEBIO

Upon completion of the final analyses of the pemziviptadil trial, we will evaluate the potential for a future trial of pemziviptadil.

Key Points: 
  • Upon completion of the final analyses of the pemziviptadil trial, we will evaluate the potential for a future trial of pemziviptadil.
  • We continue to believe pemziviptadil is a potentially valuable asset for the treatment of pulmonary arterial hypertension and other diseases.
  • Pemziviptadil, a novel, subcutaneously injected VIP analogue, is a recombinant fusion protein composed of VIP and PhaseBios proprietary elastin-like polypeptide (ELP) biopolymer.
  • These forward-looking statements speak only as of the date hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation to update these statements except as may be required by law.

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

Retrieved on: 
Wednesday, December 1, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Patient, Private Securities Litigation Reform Act, New England, Disclosure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Bentracimab, Review, Probability, NEJM, Breakthrough therapy, The New England Journal of Medicine, European Union, Forward-looking statement, Partnership, Hypertension, VIP, Clinical trial, Mark (given name), American Heart Association, Ticagrelor, Pharmacokinetics, BLA, Aspirin, PHAS, Rapids, Research, Bleeding, Hypertensive emergency, Union, FDA, Hospital, CA, LinkedIn, Harvard Medical School, Food, Pharmaceutical industry, Bentracimab (PB2452), PhaseBio, BENTRACIMAB (PB2452), PHASEBIO

We are pleased to see the publication of these highly positive interim Phase 3 results in a leading peer-reviewed scientific publication like NEJM Evidence, said John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio.

Key Points: 
  • We are pleased to see the publication of these highly positive interim Phase 3 results in a leading peer-reviewed scientific publication like NEJM Evidence, said John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio.
  • Additionally, the Phase 2a trial investigated a bentracimab regimen for the reversal of supratherapeutic doses of ticagrelor in healthy younger subjects.
  • These results are consistent with the results observed in healthy younger subjects treated with ticagrelor in the previously published Phase 1 trial.
  • PhaseBio initiated REVERSE-IT, a pivotal Phase 3 clinical trial of bentracimab, in March 2020 to support a potential Biologics License Application for bentracimab in both major bleeding and urgent surgery indications.